Retrospective analysis reveals treatment response and immune factors in relapsed large B-cell lymphoma, suggesting the role of cytokines and immune subsets.
Key Points
To analyze factors associated with clinical response to glofitamab in relapsed or refractory large B-cell lymphoma.
Retrospective evaluation of 15 patients with relapsed large B-cell lymphoma
Assessment of baseline characteristics and treatment details
Analysis of immunophenotyping and plasma cytokines
Follow-up duration averaged 6 months
46% of patients achieved complete response using glofitamab
No significant association found between immune subsets and treatment response
Trend observed in higher CD4/CD8 memory T cells in complete responders
Bulky disease associated with poorer treatment outcomes